Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Economic information and modeling report

Modeling overview

23 evidence topics · 16 sources

Summary: ICER assessment, other published economic evaluations, and commercial forecasts

The Institute for Clinical and Economic Review (ICER) assessed baxdrostat and lorundrostat for hypertension in a 2026 evidence report discussed at the “Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension”. The assessment page lists a “Final Evidence Report and Meeting Summary”, and ICER's meeting slides state that the final report would be published “on or around November 30, 2026”. ICER rated the evidence for lorundrostat or baxdrostat compared with spironolactone, eplerenone, or amiloride as “Promising but Inconclusive” in participants with resistant hypertension or intolerance of a third first-line drug (Populations 1 and 2), as “comparable or inferior” to amlodipine in participants not yet treated with a third drug (Population 3), and as insufficient to distinguish lorundrostat from baxdrostat. ICER's lifetime model used the 50 mg once-daily dose of lorundrostat and a placeholder price equal to the baxdrostat wholesale acquisition cost ($10,950 per year). At that price, lorundrostat cost $1,419,000 per QALY gained compared with spironolactone and $1,492,000 compared with amiloride, and was “More costly, less effective” than eplerenone, which ICER attributed to a 10% first-cycle discontinuation probability for lorundrostat against 7.7% for eplerenone. Lorundrostat was cost-effective in 0.0% of probabilistic simulations at $150,000 per evLY gained, and the health-benefit price benchmark for lorundrostat was $760 to $1,600 per year (85.7% to 93.0% below the placeholder price), against $1,400 to $2,500 per year for baxdrostat. Mineralys commented that the model “does not fully capture the clinical and economic benefits of ASIs”, that first-cycle discontinuation of lorundrostat (10%) was based on Launch-HTN and that of eplerenone and amiloride (7.7%) on a study of Swedish patients receiving calcium channel blockers, and that models should incorporate dynamic pricing; a commenting coalition, No Patient Left Behind, estimated a societal value-based price of $18,767 to $26,913 per year. A 2026 review states that cost-effectiveness evidence for aldosterone synthase inhibitors is still needed. No published cost-effectiveness analysis of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension was identified; a 2026 systematic review found 21 modelling studies in treatment-resistant and uncontrolled hypertension, 12 of 14 cost-utility analyses evaluating renal denervation. Published analyses report $32,732 per QALY for radiofrequency renal denervation (Medicare payer perspective), $12,900 per QALY for ultrasound renal denervation, $3,071 per QALY in a 2012 societal-perspective model in resistant hypertension, $4,400 per QALY for team-based care with non-physician titration, and cost savings of $10,162 per person for pharmacist prescribing. No sales forecast from Mineralys was identified; GlobalData forecast lorundrostat sales of $601 million in 2030, and Visible Alpha consensus projected risk-adjusted sales of $122 million in 2027 and $365 million in 2028, with analysts expecting annual revenue of $1.1 billion by 2030.

ICER cost-effectiveness model: structure, perspective, and populations

“We developed a de novo decision analytic model for this evaluation, informed by key clinical trials and prior relevant economic models” (opens the source at this quote in a new tab)

“Costs and outcomes were discounted at 3% per year. Model cycle length was three months. The analysis was conducted from a US health care sector perspective over a lifetime time horizon.” (opens the source at this quote in a new tab)

“Populations 1 and 2 were therefore reduced to a single modeled population. Population 3 was not modeled as the comparative effectiveness review rated baxdrostat and lorundrostat as “comparable or inferior” to amlodipine and, consistent with the Model Analysis Plan, cost-effectiveness in this population was to be evaluated only if the aldosterone synthase inhibitors were superior to amlodipine.” (opens the source at this quote in a new tab)

“As shown in Figure 4.1, the model included seven primary health states: 1) hypertension alone, 2) stroke, 3) myocardial infarction (MI), 4) other symptomatic coronary heart disease (CHD), 5) heart failure (HF), 6) end-stage kidney disease (ESKD), and 7) death.” (opens the source at this quote in a new tab)

“Baseline characteristics were informed by the Bax24, BaxHTN, and Launch-HTN clinical trials” (opens the source at this quote in a new tab)

“For each intervention we modeled the dose most likely to be used in clinical practice, namely the 50 mg dose for lorundrostat and the 2 mg dose for baxdrostat, both administered as once daily tablets.” (opens the source at this quote in a new tab)

ICER cost-effectiveness model: treatment effect inputs

ParameterQuoted input
SBP reduction for lorundrostat vs. placebo (mm Hg)“9.0, (95% CrI: 1.7, 16.4)”
SBP reduction for baxdrostat vs. placebo (mm Hg)“11.0 (95% CrI: 7.3, 14.6)”
SBP reduction for spironolactone vs. placebo (mm Hg)“10.1 (95% CrI: 6.7, 13.1)”
SBP reduction for eplerenone vs. placebo (mm Hg)“8.8 (95% CrI: 2.3, 15.5)”
SBP reduction for amiloride vs. placebo (mm Hg)“6.6 (95% CrI: 1.4, 11.6)”
Hazard ratio for stroke, per 5 mm Hg SBP reduction“0.87 (95% CI: 0.84, 0.91)”
Hazard ratio for ischemic heart disease, per 5 mm Hg SBP reduction“0.92 (95% CI: 0.89, 0.95)”
Hazard ratio for heart failure, per 5 mm Hg SBP reduction“0.87 (95% CI: 0.83, 0.92)”
Relative risk for ESKD, per 10 mm Hg SBP reduction“0.95 (95% CI: 0.84, 1.07)”

ICER cost-effectiveness model: base-case results at the placeholder price

TreatmentIntervention acquisition costsNon-intervention costsTotal costsQALYsevLYsLYs
Lorundrostat (placeholder price)“$28,500”“$122,200”“$150,700”“9.54”“9.54”“11.86”
Baxdrostat“$27,600”“$122,000”“$149,600”“9.55”“9.55”“11.87”
Spironolactone“$200”“$122,600”“$122,800”“9.52”“9.52”“11.83”
Eplerenone“$2,000”“$122,200”“$124,300”“9.54”“9.54”“11.86”
Amiloride“$830”“$122,500”“$123,400”“9.52”“9.52”“11.84”
Treatment and comparatorCost per QALY gainedCost per evLY gainedCost per life year gained
Lorundrostat (placeholder price) vs. spironolactone“$1,419,000”“$1,327,000”“$1,213,000”
Lorundrostat (placeholder price) vs. eplerenone“More costly, less effective”“More costly, less effective”“More costly, less effective”
Lorundrostat (placeholder price) vs. amiloride“$1,492,000”“$1,403,000”“$1,273,000”
Baxdrostat vs. spironolactone“$833,000”“$781,000”“$712,000”
Baxdrostat vs. eplerenone“$2,077,000”“$1,954,000”“$1,774,000”
Baxdrostat vs. amiloride“$851,000”“$800,000”“$727,000”

ICER cost-effectiveness model: sensitivity and probabilistic analyses

Lorundrostat (placeholder price) compared withCost-effective at $50,000 per evLY gainedCost-effective at $100,000 per evLY gainedCost-effective at $150,000 per evLY gainedCost-effective at $200,000 per evLY gained
Spironolactone“0.0%”“0.0%”“0.0%”“0.0%”
Eplerenone“0.0%”“0.0%”“0.0%”“0.2%”
Amiloride“0.0%”“0.0%”“0.0%”“0.2%”

ICER cost-effectiveness model: scenario analyses

Scenario (cost per QALY gained, lorundrostat at the placeholder price)Compared with spironolactoneCompared with eplerenoneCompared with amiloride
Modified societal perspective“$1,404,000”“Lower effect, higher cost”“$1,479,000”
Same discontinuation for all treatments“$1,322,000”“$16,455,000”“$1,382,000”
No discontinuation for all treatments“Lower effect, higher cost”“$16,956,000”“$1,436,000”
10-year treatment effect duration“$1,698,000”“Lower effect, higher cost”“$1,577,000”
20-year treatment effect duration“$1,437,000”“Lower effect, higher cost”“$1,498,000”
5-year time horizon“$28,854,000”“$166,418,000”“$10,593,000”
10-year time horizon“$5,392,000”“$123,253,000”“$3,622,000”
Minimum price for generic comparators“$1,428,000”“Lower effect, higher cost”“$1,521,000”

ICER health-benefit price benchmark and threshold prices

Intervention and outcome measureAnnual WACAnnual price at $100,000 thresholdAnnual price at $150,000 thresholdDiscount from WAC to reach threshold prices
Lorundrostat, QALYs gained (placeholder price)“$10,950”“$760”“$1,500”“86.3% - 93.0%”
Lorundrostat, evLYs gained (placeholder price)“$10,950”“$770”“$1,600”“85.7% - 93.0%”
Baxdrostat, QALYs gained“$10,950”“$1,400”“$2,400”“78.3% - 87.4%”
Baxdrostat, evLYs gained“$10,950”“$1,400”“$2,500”“77.2% - 87.1%”
Lorundrostat compared with (QALY-based)Annual price to achieve $50,000 per QALY gainedAnnual price to achieve $100,000 per QALY gainedAnnual price to achieve $150,000 per QALY gainedAnnual price to achieve $200,000 per QALY gained
Spironolactone“$600”“$980”“$1,400”“$1,700”
Eplerenone“$770”“$770”“$760”“$760”
Amiloride“$790”“$1,100”“$1,500”“$1,900”

Published cost-effectiveness analyses of lorundrostat other than the ICER assessment

No evidence found.

Published cost-effectiveness analyses of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension

No evidence found.